Top 5 Target	Count

p38 MAPK(P38 mitogen-activated protein kinase)	1
PD-1(Programmed cell death protein 1)	1
Nav1.5(Sodium channel protein type V alpha subunit)	1
PKC(Protein kinase C)	1

Drugs associated with China Medical University

Moricizine Hydrochloride

Target

Nav1.5

Mechanism

Nav1.5 blockers

Active Org.

China Medical University

Originator Org.

Shire Plc

Active Indication

Arrhythmias, Cardiac

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date19 Jun 1990

OSU-DY7

Target

p38 MAPK

Mechanism

p38 MAPK stimulants

Active Org.

China Medical University

Originator Org.

China Medical University

Active Indication

Burkitt Lymphoma [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

NCKU-21

Target-

Mechanism

Apoptosis inducers

Active Org.

China Medical University

Originator Org.

China Medical University

Active Indication

Non-Small Cell Lung Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

124

Clinical Trials associated with China Medical University

NCT06666166

/ Not yet recruitingPhase 2IIT

Exploratory Clinical Study of SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

To evaluate the effectiveness and safety of SHR-A1811 combined with apatinib in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.

Start Date01 Dec 2024

Sponsor / Collaborator

China Medical University

[+1]

NCT06595043

/ RecruitingNot ApplicableIIT

Effects of Different Occlusion Angles of Disposable Tracheal Blocker on Right One-lung Ventilation: a Multi-center, Prospective, Randomized Controlled Trial

This trial is a practical, multicenter, prospective, parallel grouping, randomized controlled,two-arm study. This study will be conducted in three centers including the First Hospital of China Medical University, Seoul National University Hospital and the University Clinical Center of Serbia. The investigators aim to investigate the effect of different occlusion angles of disposable tracheal blocker on right one-lung ventilation

Start Date09 Oct 2024

Sponsor / Collaborator

China Medical University

NCT06604221

/ Not yet recruitingNot ApplicableIIT

The Impact of Resistance Exercise on Symptom Burden in Older Patients Undergoing Maintenance Hemodialysis

The goal of this clinical trial is to learn if an intradialytic resistance exercise intervention works to reduce the symptom burden in older maintenance hemodialysis patients. It will also learn about safety of the intradialytic resistance exercise intervention program. The main questions it aims to answer are:
1. Does intradialytic resistance exercise effectively improve the number, frequency, and severity of symptoms in older patients?
2. What adverse events may occur among older dialysis patients during exercise?
Researchers will compare older dialysis patients who undergo the intradialytic resistance exercise intervention with those receiving standard care to observe whether resistance exercise can improve symptom burden.
Participants will:
1. Take an intradialytic resistance exercise intervention program developed through joint decision-making by rehabilitation experts, dialysis center physicians, nurses, and patients, conducted three times a week for 20 minutes each session, over a duration of three months.
2. Visit the hospital a monthly for texts and examinations.
3. Keep a diary of the types and frequency of adverse events during and after the exercise sessions.

Start Date03 Oct 2024

Sponsor / Collaborator

China Medical University

[+1]

100 Clinical Results associated with China Medical University

0 Patents (Medical) associated with China Medical University

3,299

Literatures (Medical) associated with China Medical University

31 Dec 2025·ANNALS OF MEDICINE

Nailfold capillary abnormalities as indicators of diabetic nephropathy progression: a cross-sectional study in type 2 diabetes

Article

Author: Chiang, John Y. ; Liao, Pei-Yung ; Huang, Ssu-Wei ; Chang, Hen-Hong ; Lo, Lun-Chien ; Hsu, Po-Chi

BACKGROUND:

Type 2 diabetes mellitus (DM) leads to chronic hyperglycemia and microvascular complications, including diabetic nephropathy (DN). Nailfold videocapillaroscopy (NVC) is a non-invasive method for assessing the microvascular abnormalities and may aid in early DN detection. This study investigates the correlation between DN and nailfold capillary abnormalities in type 2 DM.

METHODS:

This prospective cross-sectional study involved 453 participants with type 2 DM, divided into 3 groups based on estimated glomerular filtration rate (eGFR) or albumin-to-creatinine (A/C) ratio. Chronic kidney disease (CKD) risk categories based on the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines. Participants underwent structured interviews, clinical assessments, and laboratory tests. NVC was performed to assess capillary morphology, distribution, density, and blood flow.

RESULTS:

Significant differences in NVC measurements were observed across eGFR groups, with higher NVC scores and more severe capillary abnormalities noted in lower eGFR groups. The 'comma-like' capillary distribution pattern (23.08%, p = 0.016), more ratio of ramified capillaries (p = 0.0137) were observed in the eGFR <30 ml/min/1.73m² group. Reduced fundus transparency (p = 0.0015) and impaired visibility of the sub-venous plexus (p = 0.0016) were noted in the lower eGFR groups. Capillary lengths, both input and mean, were shorter in the A/C ratio > 300 mg/g group (p = 0.0382 and p = 0.0478, respectively). The NVC score was higher in the A/C ratio > 300 mg/g groups (p = 0.0028).

CONCLUSION:

Nailfold capillary abnormalities correlate with DN severity, indicating their potential as a non-invasive biomarker for early DN detection and monitoring in type 2 DM.

31 Dec 2025·ANNALS OF MEDICINE

Combination of reverse shock index and simplified motor score as a strong discriminator of trauma outcomes

Article

Author: Ma, Hon-Ping ; Wu, Meng-Yu ; Chung, Jui-Yuan ; Lin, Mau-Roung ; Yiang, Giou-Teng ; Chen, Sy-Jou ; Chien, Ding-Kuo ; Chu, Chi-Ming

BACKGROUND:

The reverse shock index multiplied by simplified motor score (rSI-sMS) is a novel and rapid measure for assessing injury severity in patients with trauma in prehospital settings; however, its discriminant ability requires further validation.

METHODS:

A retrospective cohort study was conducted from trauma database of Taipei Tzu Chi Hospital to compare the accuracy of the rSI-sMS with that of the shock index, modified shock index, reverse shock index multiplied by the Glasgow Coma Scale (rSI-GCS), and the reverse shock index multiplied by GCS motor subscale (rSI-GCSM) for discriminating in-hospital mortality, intensive care unit (ICU) admissions, prolonged ICU stays ≥14 days, and prolonged hospital stays ≥30 days in patients with trauma.

RESULTS:

A total of 11,760 patients from the trauma database were included. rSI-sMS had significantly better accuracy in discriminating in-hospital mortality, ICU admissions, prolonged ICU stays (≥14 days), and prolonged hospital stays (≥30 days) than the shock index, modified shock index, and rSI-GCSM, whereas its accuracy was similar to that of the rSI-GCS. Furthermore, rSI-sMS had better accuracy for discriminating clinical outcomes in patients with an injury severity score (ISS) ≥16, motor vehicle collisions, falls, no chronic disease, and cardiovascular disease as well as in geriatric and nongeriatric patients. In patients with mixed and isolated brain injuries, rSI-sMS accurately discriminated the four clinical outcomes, similar to rSI-GCS. The optimal cutoff value of rSI-sMS had a discriminant ability of 85.0, 78.6, 75.2, and 81.0% for in-hospital mortality, ICU admissions, ICU stay ≥14 days, and hospital stays of ≥30 days, respectively.

CONCLUSIONS:

Compared with the shock index, modified shock index, and rSI-GCSM, rSI-sMS is a more accurate field triage scoring system for discriminating in-hospital mortality, ICU admissions, prolonged ICU stay, and prolonged hospital stays in patients with trauma.

31 Dec 2025·Future Science OA

TWEAK/Fn14 axis may promote vascular smooth muscle cell senescence via p38 signaling pathway: preliminary evidence

Article

Author: Wei, Chunyang ; Qi, Guoxian ; Wang, Yanfu ; Miao, Zhuang ; Zhang, Hua ; Liu, Xiaoying

AIM:

The primary objective of this study is to investigate the impact of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its functional receptor, fibroblast growth factor-inducible 14 (Fn14), on the process of vascular smooth muscle cell (VSMC) senescence.

METHODS:

Rat arterial VSMCs were cultured with angiotensin II to establish a model of premature senescence. The effects of TWEAK and Fn14 on senescent VSMCs were evaluated. Additionally, the role of p38 phosphorylation pathway in the effect of TWEAK on VSMCs senescence was assessed.

RESULTS:

Expressions of TWEAK and Fn14 were significantly elevated in senescent VSMCs. TWEAK activated the p38 phosphorylation pathway and promoted the SA-β-gal staining and P53 expression.

CONCLUSION:

These preliminary findings suggest that the TWEAK/Fn14 axis may play a crucial role in promoting VSMC senescence.

News (Medical) associated with China Medical University

05 Feb 2025

·www.prnewswire.com

China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment

TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the latest developments and trends in healthcare technology in Taiwan. China Medical University (CMU) and Healthcare System unveiled groundbreaking advancements in AI-driven drug discovery and cancer therapy at the latest 8th Healthcare Expo. These achievements cement CMU and Healthcare System's position as a global leader in healthcare innovation, setting new benchmarks for the biomedical industry. Continue Reading CMU and Healthcare System (Taiwan) highlights groundbreaking AI-driven drug discovery and unveils the latest advancements in healthcare innovations and their clinical applications. Dr. Chang-Hai Tsai, Chairman of CMU and Healthcare System, emphasized the institution's commitment to cutting-edge research and international collaboration. By partnering with Kyoto University, CMU and Healthcare System has established a global research center to spearhead advancements in cancer research, regenerative medicine, and AI-powered drug discovery. A Milestone in Cancer Therapy: Allogeneic CAR-T Achieves 90% Tumor Reduction CMU and Healthcare System revealed the world's first allogeneic CAR-T therapy for solid cancers, developed by Ever Supreme Bio Technology. This therapy has demonstrated an unprecedented tumor reduction rate of over 90% in pre-clinical studies. Human clinical trials are underway, with FDA approval marking a pivotal moment in solid tumor treatment. Precision Medicine Breakthroughs: Exosome Technology and AI Integration Shine-On Biomedical and Shine Out Bio Technology are revolutionizing precision medicine through exosome technology. Their innovations include: SOA101 Trispecific Antibody: A nanobody-based platform combining two immune checkpoint inhibitors, now in FDA-reviewed Phase I/IIa trials for cancer therapy. SOB100 HLA-G Targeted Exosome: Delivering drugs with pinpoint precision to tumors, this platform enhances efficacy while minimizing side effects. Human clinical trials for these technologies are set to begin in 2025, promising to transform cancer and neurodegenerative disease treatments. AI-Powered Healthcare Solutions CMU and Healthcare System's AI-driven initiatives include: Child Growth Assessment System: AI generates detailed diagnostic reports for personalized treatment planning. HiThings Tele-ICU: This state-of-the-art system integrates real-time patient data with 3D modeling for enhanced critical care management. Smart Health Scheduling: AI optimizes health examination processes to streamline care delivery. Computer-assisted detection platform for Tc-99mTRODAT-1: AI analyzes brain images and visual scales to assist in diagnosing central nervous system motor disorders. Long Term Care Record System and Medical Information Revise Assistant (MIRA): Enhances medical record accuracy and efficiency, allowing healthcare professionals to focus on patient care. Specialized Healthcare Innovations CMUH continues to lead in cutting-edge treatments: MRgFUS for Parkinson's Disease: A non-invasive, MRI-guided therapy offering new hope for patients. Proton Therapy Center: Delivering precision cancer treatments with reduced side effects. Gout Risk Prediction: Genetic testing for tailored patient management. Global Collaboration with Kyoto University The newly established CMU-Kyoto University Global Research Center strengthens ties in cancer research, translational medicine, and regenerative therapies. As part of this initiative, CMU Research Park integrates academic and industrial expertise to drive groundbreaking developments from laboratory research to clinical applications. Advancing Healthcare Through Innovation Dr. Der-Yang Cho, Superintendent of CMUH, highlighted AI's transformative role in drug discovery and clinical applications. CMU and Healthcare System remains at the forefront of healthcare innovation, bridging AI, biotechnology, and clinical practice to redefine the future of medicine. CMU and Healthcare System's pioneering work at the Healthcare Expo Taiwan underscores Taiwan's growing influence in global healthcare. With a focus on collaboration and innovation, CMU and Healthcare System is not just shaping the future of medicine—it's leading it. Contact Carolyn Chen [email protected] SOURCE China Medical University Hospital WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

13 Jan 2025

·www.prnewswire.com

CMU and Healthcare System Secures Unprecedented 17 Awards at the 2024 Taiwan National Innovation Awards

TAICHUNG, Jan. 12, 2025 /PRNewswire/ -- The Taiwan National Innovation Awards, regarded as the pinnacle of excellence in the biomedical and healthcare sectors, recognize the most transformative breakthroughs that push boundaries and redefine global standards. At the 21st annual awards in 2024, the China Medical University (CMU) and Healthcare System achieved an extraordinary milestone, sweeping 17 awards across three prestigious categories: two Corporate Innovation Awards, six Academic-Research Innovation Awards, and nine Clinical Innovation Awards. This unparalleled success cements CMU and Healthcare System's position as a trailblazer in biotechnology, smart healthcare, and innovative medical devices. Continue Reading At the 2024 Taiwan National Innovation Awards, CMU and Healthcare System achieved an extraordinary milestone, sweeping 17 awards through cell therapy, smart healthcare innovations, and exosome-based technology. A shining example of CMU and Healthcare System's innovative prowess is the groundbreaking CAR001 cell therapy developed by its spin-off, Ever Supreme Bio Technology. This revolutionary treatment employs allogeneic CAR and BiTE-GDT technologies to target solid tumors with unprecedented precision. Utilizing artificial intelligence, the research team identified HLA-G as a critical target for solid tumors, enabling the development of the CAR001 (CAR-T) technique. In preclinical animal trials, this breakthrough therapy achieved an astounding 90% tumor eradication rate, with results published in world-leading medical journals. The therapy has also received Phase I and IIa clinical trial approvals in both Taiwan and the United States, marking a pivotal step toward clinical application. Adding to the excitement, CMU and Healthcare System's innovations were showcased during the highly anticipated "Demo Day" segment of the awards. This platform features the most exceptional teams presenting their work to top Taiwanese investors for live evaluation and feedback. Ever Supreme Bio Technology stood out as one of the ten chosen teams, further underscoring the global potential and competitive edge of its technology. CMU and Healthcare System's achievements extend beyond cutting-edge therapies. Its pioneering use of artificial intelligence spans critical areas, including drug discovery, myocardial infarction treatment, infection and sepsis management, remote dialysis, image analysis, and medical education. Moreover, CMU and Healthcare System has redefined possibilities in exosome-based technology, offering transformative solutions for cancer and neurodegenerative diseases such as Parkinson's. The precision of its targeted exosome delivery system significantly enhances treatment outcomes, heralding new hope for patients with conditions once considered intractable. As a hub of innovation, CMU and Healthcare System exemplifies the synergy between research excellence and global collaboration. By forging partnerships with world-class academic and medical institutions, CMU and Healthcare System is accelerating the clinical adoption of groundbreaking technologies. Its unwavering commitment to advancing biomedical and smart healthcare innovation is transforming patient care and driving profound, lasting impact on the global stage. The future of healthcare has never looked brighter—and CMU and Healthcare System is at the forefront, leading the charge. Media contact: Carolyn Chen, [email protected] SOURCE China Medical University Hospital WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Cell TherapyClinical Result

100 Deals associated with China Medical University

100 Translational Medicine associated with China Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Moricizine Hydrochloride ( Nav1.5 )	Arrhythmias, Cardiac More	Approved
OSU-DY7 ( p38 MAPK )	Chronic Lymphocytic Leukemia More	Preclinical
8-Methoxyflindersine	Colorectal Cancer More	Preclinical
NCKU-21	Non-Small Cell Lung Cancer More	Preclinical
TCH-1116 ( PKC )	Inflammation More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis